Completed PHASE3 INTERVENTIONAL 2-arm NCT00856609

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Interventions Byetta (exenatide) Metabolic Chamber Placebo Weight loss

Updated 8 times since 2017 Last updated: May 23, 2019 Started: Mar 3, 2009 Primary completion: Sep 19, 2016 Completion: Sep 19, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Obesity and Weight Loss, this trial is completed. The trial is conducted by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Jul 2019 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Feb 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Phoenix, United States